NEW YORK, NY / ACCESS Newswire / August 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ:TEM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants […]

NEW YORK, NY / ACCESS Newswire / August 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or "the Company") (NASDAQ:RCKT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants

NEW YORK CITY, NY / ACCESS Newswire / August 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants

(NASDAQ:TMC), TMC published two technical economic assessments prepared in accordance with Subpart 1300 of Regulation S-K highlighting a total combined project value of $23.6 billion, showing potential economic viability of its NORI-D Project and significant scalability across other NORI and TOML areas World-first Pre-Feasibility Study (PFS) for a polymetallic nodule project in the NORI-D area

(NYSE:BRC), MILWAUKEE, Aug. 04, 2025 (GLOBE NEWSWIRE) — Brady Corporation (NYSE: BRC) (“Brady,” “our,” “we”) announced today that it has acquired Mecco Partners, LLC (“Mecco”) for approximately $20 million, and for the fiscal year ending July 31, 2026, Brady expects revenue of approximately $20 million. Brady funded the acquisition with cash on hand. Mecco specializes

ATV-1601 is a first-in-class allosteric selective inhibitor of AKT1 E17K Pan-AKT inhibitors offer limited efficacy for patients with AKT1 E17K-driven mutant tumors due to insufficient inhibition of the AKT1 E17K mutation and AKT2-driven tolerability issues In preclinical studies, ATV-1601 has demonstrated enhanced target inhibition, superior efficacy, and improved tolerability compared to pan-AKT inhibitors CAMBRIDGE, Mass.,

NEW YORK, NY / ACCESS Newswire / August 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Reckitt Benckiser Group PLC ("Reckitt" or "the Company") (OTCMKTS:RBGLY) and certain of its officers. Class Definition This lawsuit seeks to recover damages against

NEW YORK CITY, NY / ACCESS Newswire / August 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Vestis Corporation ("Vestis" or "the Company") (NYSE:VSTS) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants

Tower Semiconductor Reports 2025 Second Quarter Financial Results GlobeNewswire August 04, 2025 Quarter-over-quarter and year-over-year revenue growth Providing guidance for accelerated revenue growth in the third quarter MIGDAL HAEMEK, Israel, Aug. 04, 2025 (GLOBE NEWSWIRE) — Tower Semiconductor (NASDAQ/TASE: TSEM) reports today its results for the second quarter ended June 30, 2025. Second Quarter of

Atavistik Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ATV-1601 in Patients with AKT1 E17K-mutant Solid Tumors GlobeNewswire August 04, 2025 ATV-1601 is a first-in-class allosteric selective inhibitor of AKT1 E17K Pan-AKT inhibitors offer limited efficacy for patients with AKT1 E17K-driven mutant tumors due to insufficient inhibition of the AKT1 E17K mutation